**Author details**

Yves Lecarpentier1\* and Alexandre Vallée2

\*Address all correspondence to: yves.c.lecarpentier@gmail.com

1 Clinical Research Center, Meaux Hôpital, Meaux, France

2 Jules Verne University of Picardie, Amiens, France and Experimental and Clinical Neuro‐ sciences Laboratory, University of Poitiers, France

## **References**


[8] Lecarpentier Y, Claes V, Duthoit G, Hebert JL: Circadian rhythms, Wnt/beta-catenin pathway and PPAR alpha/gamma profiles in diseases with primary or secondary cardiac dysfunction. Front physiology 2014, 5:429. DOI: 10.3389/fphys.2014.00429

**Author details**

264 Update on Amyotrophic Lateral Sclerosis

**References**

jbc.M403143200

2010.03.010

Yves Lecarpentier1\* and Alexandre Vallée2

\*Address all correspondence to: yves.c.lecarpentier@gmail.com

2 Jules Verne University of Picardie, Amiens, France and Experimental and Clinical Neuro‐

[1] Gerhold DL, Liu F, Jiang G, Li Z, Xu J, Lu M, Sachs JR, Bagchi A, Fridman A, Holder DJ et al.: Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists. Endocrinology 2002,

[2] Moldes M, Zuo Y, Morrison RF, Silva D, Park BH, Liu J, Farmer SR: Peroxisomeproliferator-activated receptor gamma suppresses Wnt/beta-catenin signalling during

[3] Sharma C, Pradeep A, Wong L, Rana A, Rana B: Peroxisome proliferatoractivated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway. The journal of biological chemistry 2004, 279(34):35583–35594. DOI: 10.1074/

[4] Garcia-Gras E, Lombardi R, Giocondo MJ, Willerson JT, Schneider MD, Khoury DS, Marian AJ: Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglo‐ bin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. The

[5] Liu J, Wang H, Zuo Y, Farmer SR: Functional interaction between peroxisome prolif‐ erator-activated receptor gamma and beta-catenin. Molecular and cellular biology

[6] Takada I, Kouzmenko AP, Kato S: Wnt and PPARgamma signaling in osteoblastogen‐

[7] Lu D, Carson DA: Repression of beta-catenin signaling by PPAR gamma ligands. European journal of pharmacology 2010, 636(1–3):198–202. DOI: 10.1016/j.ejphar.

1 Clinical Research Center, Meaux Hôpital, Meaux, France

143(6):2106–2118. DOI: 10.1210/endo.143.6.8842

adipogenesis. Biochemistry journal 2003, 376(Pt 3):607–613.

journal of clinical investigation 2006, 116(7):2012–2021.

2006, 26(15):5827–5837. DOI: 26/15/5827 [pii]10.1128/MCB.00441-06

esis and adipogenesis. Nat Rev Rheumatol 2009, 5(8):442–447.

sciences Laboratory, University of Poitiers, France


[32] Chen Y, Guan Y, Zhang Z, Liu H, Wang S, Yu L, Wu X, Wang X: Wnt signaling pathway is involved in the pathogenesis of amyotrophic lateral sclerosis in adult transgenic mice. Neurological research 2012, 34(4):390–399. DOI: 10.1179/1743132812Y.0000000027

[21] He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW: Identification of c-MYC as a target of the APC pathway. Science 1998,

[22] Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A: The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proceedings of the national academy of sciences of the United States of America 1999, 96(10):5522–5527.

[23] Angers S, Moon RT: Proximal events in Wnt signal transduction. Nature reviews

[24] Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz M, Moller DE, Berger J: Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochemical and biophysical research communica‐

[25] Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S et al.: The organization, promoter analysis, and expression of the human PPARgamma gene. The journal of biological chemistry 1997, 272(30):18779–

[26] Katsouri L, Blondrath K, Sastre M: Peroxisome proliferator-activated receptor-gamma cofactors in neurodegeneration. IUBMB life 2012, 64(12):958–964. DOI: 10.1002/iub.1097

[27] Kapadia R, Yi JH, Vemuganti R: Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Frontiers in bioscience: a journal and virtual library

[28] Gray E, Ginty M, Kemp K, Scolding N, Wilkins A: The PPAR-gamma agonist piogli‐ tazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function. Journal of neuroinflammation 2012, 9:63. DOI:

[29] Romera C, Hurtado O, Mallolas J, Pereira MP, Morales JR, Romera A, Serena J, Vivancos J, Nombela F, Lorenzo P et al.: Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection. Journal of cerebral blood flow and metabolism: official journal of the international society of cerebral blood flow and metabolism 2007, 27(7):1327–1338. DOI: 10.1038/

[30] Jitrapakdee S, Slawik M, Medina-Gomez G, Campbell M, Wallace JC, Sethi JK, O'Ra‐ hilly S, Vidal-Puig AJ: The peroxisome proliferator-activated receptor-gamma regu‐ lates murine pyruvate carboxylase gene expression in vivo and in vitro. The journal of

biological chemistry 2005, 280(29):27466–27476. DOI: 10.1074/jbc.M503836200

cardiomyopathy (ARVC). Cardiovascular research 2009,84:83–90.

[31] Djouadi F, Lecarpentier Y, Hebert JL, Charron P, Bastin J, Coirault C: A potential link between PPAR signaling and the pathogenesis of arrhythmogenic right ventricular

molecular cell biology 2009, 10(7):468–477. DOI: 10.1038/nrm2717

281(5382):1509–1512.

266 Update on Amyotrophic Lateral Sclerosis

tions 1996, 224(2):431–437.

2008, 13:1813–1826.

10.1186/1742-2094-9-63

sj.jcbfm.9600438

18789.


pathways to promote cell survival in the absence of soluble survival factors. American journal of physiology renal physiology 2005, 288(4):F703–713. DOI: 10.1152/ajprenal. 00189.2004


pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PloS one 2012, 7(6):e37885. DOI: 10.1371/journal.pone.0037885

[55] Liang H, Ward WF, Jang YC, Bhattacharya A, Bokov AF, Li Y, Jernigan A, Richardson A, Van Remmen H: PGC-1alpha protects neurons and alters disease progression in an amyotrophic lateral sclerosis mouse model. Muscle nerve 2011, 44(6):947–956. DOI: 10.1002/mus.22217

pathways to promote cell survival in the absence of soluble survival factors. American journal of physiology renal physiology 2005, 288(4):F703–713. DOI: 10.1152/ajprenal.

[44] Galli C, Piemontese M, Lumetti S, Manfredi E, Macaluso GM, Passeri G: GSK3binhibitor lithium chloride enhances activation of Wnt canonical signaling and osteo‐ blast differentiation on hydrophilic titanium surfaces. Clinical oral implants research

[45] Gould TD, Manji HK: The Wnt signaling pathway in bipolar disorder. Neuroscientist

[46] Valvezan AJ, Klein PS: GSK-3 and Wnt signaling in neurogenesis and bipolar disorder.

[47] Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G: Riluzole in the treatment of mood and anxiety disorders. CNS drugs 2008, 22(9):761–786.

[48] Chen YC, Wu JS, Tsai HD, Huang CY, Chen JJ, Sun GY, Lin TN: Peroxisome prolifer‐ ator-activated receptor gamma (PPAR-gamma) and neurodegenerative disorders.

[49] Kiaei M: Peroxisome proliferator-activated receptor-gamma in amyotrophic lateral

[50] Shibata N, Kawaguchi-Niida M, Yamamoto T, Toi S, Hirano A, Kobayashi M: Effects of the PPARgamma activator pioglitazone on p38 MAP kinase and IkappaBalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis. Neuro‐ pathology: official journal of the Japanese society of neuropathology 2008, 28(4):387–

[51] Benedusi V, Martorana F, Brambilla L, Maggi A, Rossi D: The peroxisome proliferatoractivated receptor gamma (PPARgamma) controls natural protective mechanisms against lipid peroxidation in amyotrophic lateral sclerosis. The journal of biological

[52] Joardar A, Menzl J, Podolsky TC, Manzo E, Estes PS, Ashford S, Zarnescu DC: PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43.

[53] Schutz B, Reimann J, Dumitrescu-Ozimek L, Kappes-Horn K, Landreth GE, Schurmann B, Zimmer A, Heneka MT: The oral antidiabetic pioglitazone protects from neurode‐ generation and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. The journal of neuroscience: the official journal of the society for neuroscience 2005, 25(34):7805–7812. DOI: 10.1523/JNEUROSCI.2038-05.2005

[54] Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, Kassubek J, Fischer W, Steiner F, Lindauer E, Otto M et al.: A randomized, double blind, placebo-controlled trial of

Human molecular genetics 2015, 24(6):1741–1754. DOI: 10.1093/hmg/ddu587

Molecular neurobiology 2012, 46(1):114–124. DOI: 10.1007/s12035-012-8259-8

sclerosis and Huntington's disease. PPAR research 2008, 2008:418765.

chemistry 2012, 287(43):35899–35911. DOI: 10.1074/jbc.M112.366419

398. DOI: 10.1111/j.1440-1789.2008.00890.x

2013, 24(8):921–927. DOI: 10.1111/j.1600-0501.2012.02488.x

Front Mol Neurosci 2012, 5:1. DOI: 10.3389/fnmol.2012.00001

00189.2004

268 Update on Amyotrophic Lateral Sclerosis

2002, 8(5):497–511.


[64] d'Abramo C, Massone S, Zingg JM, Pizzuti A, Marambaud P, Dalla Piccola B, Azzi A, Marinari UM, Pronzato MA, Ricciarelli R: Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. Biochemistry journal 2005, 391(Pt 3):693–698. DOI: 10.1042/BJ20050560 [65] Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR: Rosiglita‐ zone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Experimental

[66] Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD: Efficacy of rosiglitazone in a genetically defined popula‐ tion with mild-to-moderate Alzheimer's disease. Pharmacogenomics journal 2006, 6(4):

[67] Escribano L, Simon AM, Gimeno E, Cuadrado-Tejedor M, Lopez de Maturana R, Garcia-Osta A, Ricobaraza A, Perez-Mediavilla A, Del Rio J, Frechilla D: Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology: official publication of the American college of neuropsychopharmacology 2010, 35(7):1593–1604. DOI:

neurology 2006, 199(2):265–273. DOI: 10.1016/j.expneurol.2006.01.018

246–254. DOI: 10.1038/sj.tpj.6500369

10.1038/npp.2010.32

270 Update on Amyotrophic Lateral Sclerosis

*Edited by Humberto Foyaca Sibat and Lurdes de Fatima Ibañez Valdés*

This book contains selected peer-reviewed chapters which cover updated information on ALS written by international researchers. Update on Amyotrophic Lateral Sclerosis is comprised of 13 chapters from some of the world's top central nervous system researchers and neurologists to provide a timely review of the most recent developments in ALS, covering historic aspects, experimental animal models, genetics, pathogenesis, clinical aspects and imagenology among others. Contributors from Belgium, France, Japan, India, Italy, Mexico, Russia, South Africa, and Switzerland have collaborated enthusiastically and efficiently, dedicating their time to create this reader-friendly yet comprehensive work which includes many explanatory figures, tables and photos to enhance legibility and make the book clinically useful. We are looking forward with confidence and pride in the remarkable role that this book will play for a new vision and mission.

Update on Amyotrophic Lateral Sclerosis

Update on Amyotrophic

Lateral Sclerosis

*Edited by Humberto Foyaca Sibat* 

*and Lurdes de Fatima Ibañez Valdés*

Photo by iDesign / CanStock